A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder

Biological Psychiatry
Adam J GuastellaMark R Dadds

Abstract

Pilot research has suggested that D-cycloserine (DCS) enhances treatment outcomes for anxiety disorders when employed as an adjunct to exposure therapy (ET). The aim of this study was to determine whether 50 mg of DCS enhances ET for social anxiety disorder (SAD) according to a comprehensive set of symptom and life impairment measures. In a randomized double-blind placebo-controlled trial, we administered 50 mg of DCS or placebo in combination with ET to 56 participants who met primary diagnosis for SAD. Participants administered DCS reported greater improvement on measures of symptom severity, dysfunctional cognitions, and life-impairment from SAD in comparison with placebo-treated participants. Effect sizes were mostly in the medium range. Results also indicated that the amount of adaptive learning about one's ability to give speeches in front of an audience interacted with DCS to enhance treatment outcome. This study shows that the administration of DCS before ET enhances treatment outcomes for SAD. Results also provide the first preliminary evidence to suggest that DCS moderates the relationship between a reduction in negative appraisals about one's speech performance and improvement in overall SAD symptoms.

Associated Clinical Trials

References

May 1, 1987·The British Journal of Psychiatry : the Journal of Mental Science·M R Liebowitz
Apr 1, 1996·Behaviour Research and Therapy·R M Rapee, K Hayman
Dec 6, 2002·The International Journal of Neuropsychopharmacology·Uriel Heresco-LevyTamar Cohen
Mar 3, 2004·Journal of Abnormal Psychology·Maree J Abbott, Ronald M Rapee
Oct 7, 2004·Learning & Memory·Rick RichardsonJacquelyn Cranney
Mar 8, 2006·Archives of General Psychiatry·Stefan G HofmannMichael W Otto
Jul 11, 2006·Journal of Psychiatric Research·Adam J GuastellaRick Richardson
Sep 12, 2006·Behaviour Research and Therapy·Adam J GuastellaRick Richardson
Jun 26, 2007·Biological Psychiatry·Matt G KushnerEdna B Foa
Jul 31, 2007·Behaviour Research and Therapy·Stefan G Hofmann
Sep 4, 2007·The British Journal of Psychiatry : the Journal of Mental Science·Ronald M RapeeJonathan E Gaston

❮ Previous
Next ❯

Citations

Feb 27, 2009·Psychopharmacology·Devin MuellerGregory J Quirk
Mar 21, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Julia M Langton, Rick Richardson
Feb 20, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Bronwyn M Graham, Rick Richardson
Aug 14, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Daisuke YamadaMasayuki Sekiguchi
Feb 5, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Bronwyn M Graham, Rick Richardson
Jul 16, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Karyn M MyersMichael Davis
Jul 2, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jessica McCallumRick Richardson
Apr 22, 2008·Nature Reviews. Drug Discovery·Gerard SanacoraHusseini K Manji
Nov 1, 2013·Nature Reviews. Drug Discovery·Robert J Harvey, Benjamin K Yee
Sep 21, 2012·Cognitive Behaviour Therapy·Cassidy A GutnerStefan G Hofmann
Dec 14, 2011·Current Opinion in Psychiatry·Charles B Pull
Apr 25, 2008·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Mark R Dadds, Tracy Rhodes
Apr 26, 2012·Genes, Brain, and Behavior·R Andero, K J Ressler
Feb 22, 2012·Journal of Psychopharmacology·Floris KlumpersJohanna M P Baas
Jun 19, 2013·Biology of Mood & Anxiety Disorders·Stefan G HofmannHannah Boettcher
Feb 19, 2010·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Shashank M DravidStephen F Traynelis
May 15, 2012·The Journal of Clinical Psychiatry·Allyson BontempoMichael H Bloch
Jan 16, 2014·Annual Review of Medicine·JoAnn DifedeJudith Cukor
Sep 24, 2013·Neurobiology of Learning and Memory·Christine A RabinakK Luan Phan
Feb 12, 2014·Neurobiology of Learning and Memory·Kathryn D BakerRick Richardson
Dec 19, 2012·Annual Review of Clinical Psychology·David H BarlowAmantia A Ametaj
Jun 29, 2014·Expert Review of Neurotherapeutics·Joseph F McGuireEric A Storch
Aug 9, 2011·Expert Opinion on Pharmacotherapy·Laura C PratchettRachel Yehuda
May 31, 2013·Expert Opinion on Investigational Drugs·Joanna M Wierońska, Andrzej Pilc
May 21, 2009·Expert Opinion on Emerging Drugs·Dewleen G BakerVictoria B Risbrough
Jan 19, 2011·Expert Opinion on Pharmacotherapy·Franklin R Schneier
Aug 20, 2011·The American Journal of Drug and Alcohol Abuse·Stefan G HofmannKathleen M Kantak
Oct 25, 2008·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Borwin BandelowJohann Vega
Dec 25, 2012·Biological Psychiatry·Nesha S BurghardtJoseph E LeDoux
Oct 2, 2012·Journal of Anxiety Disorders·Frank J FarachPeter P Roy-Byrne
Jun 15, 2012·Journal of Psychiatric Research·Brett T LitzStefan G Hofmann
May 15, 2012·Biological Psychiatry·Karyn M Myers, William A Carlezon

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.